Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Valerievna Samburova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracellular Vesicles from iPSC-Derived Glial Progenitor Cells Prevent Glutamate-Induced Excitotoxicity by Stabilising Calcium Oscillations and Mitochondrial Depolarisation

    by Margarita Shedenkova, Anastasiia Gurianova, Irina Krasilnikova, Anastasia Sudina, Evgeny Karpulevich, Yaroslav Maksimov, Marina Samburova, Egor Guguchkin, Zlata Nefedova, Valentina Babenko, et al.

    Neurodegenerative diseases pose a significant challenge to modern medicine. Despite significant advances in neurology, current therapeutic approaches often prove insufficient to treat such disorders. This study investigates the neuroprotective effect of extracellular vesicles derived from glial derivates of human-induced pluripotent stem cells. The extracellular vesicle’s cargo was characterised by proteomic analysis. The neuroprotective effect was assessed using a model of glutamate excitotoxicity performed on a primary culture of cortical neuroglial cells. The viability of cells was estimated using the MTT test and morphometric analyses. A comprehensive methodology was applied to investigate intracellular mechanisms, integrating assessments of intracellular calcium concentrations, mitochondrial membrane potential, and targeted inhibition of the PI3K-Akt pathway. Transcriptomic analysis of neuroglial cultures was used to validate the role of obtained mechanisms of extracellular vesicle’s neuroprotective effect. The obtaining results demonstrated the improvement of neuronal survival by reducing intracellular calcium levels and stabilising mitochondrial membrane potential under glutamate-induced excitotoxicity via PI3K-Akt signalling pathway activation. Moreover, the vesicles contained proteins that contribute to preventing apoptotic processes, activating regeneration of the nervous system, and modulating calcium ion transport and are associated with redox processes. Further transcriptomic analyses of neuroglial cultures treated with EVs showed an up-regulation of genes associated with regeneration, inhibition of calcium ion transport, regulation of membrane depolarisation, and negative regulation of apoptotic pathways.


  • Open Access

    Extracellular Vesicles from iPSC-Derived Glial Progenitor Cells Prevent Glutamate-Induced Excitotoxicity by Stabilising Calcium Oscillations and Mitochondrial Depolarization

    by Margarita Shedenkova, Anastasiia Gurianova, Irina Krasilnikova, Anastasia Sudina, Evgeny Karpulevich, Yaroslav Maksimov, Marina Valerievna Samburova, Egor Guguchkin, Zlata Nefedova, Valentina Babenko, et al.

    Neurodegenerative diseases pose a significant challenge to modern medicine. Despite significant advances in neurology, current therapeutic approaches often prove insufficient to treat such disorders. This study investigates the neuroprotective effect of extracellular vesicles derived from glial derivates of human induced pluripotent stem cells. The extra-cellular vesicle’s cargo was characterised by proteomic analysis. They neuroprotective ef-fect was assessed using a model of glutamate excitotoxicity performed on primary culture of cortical neurons. The viability of cortical neurons was estimated using the MTT test and morphometric analyses. A comprehensive methodology was applied to investigate intra-cellular mechanisms, integrating assessments of intracellular calcium concentrations, mitochondrial membrane potential, and targeted inhibition of the PI3K‑Akt pathway. Transcriptomic analysis of cortical neurons was used to validated the role of obtained mechanisms of extracellular vesicle’s neuroprotective effect. The obtaining results demon-strated the improvement of neuronal survival by reducing intracellular calcium levels, and stabilizing mitochondrial membrane potential under glutamate-induced excitotoxi-city via PI3K-Akt signaling pathway activation. Moreover, the vesicles contained proteins that contribute to preventing apoptotic processes, activating regeneration of nervous sys-tem, modulating of calcium ion transport and associated with redox processes. Further transcriptomic analyses of neuroglial cultures treated with EVs showed up-regulation of genes associated with regeneration, inhibition of calcium ion transport, regulation of membrane depolirisation and negative regulation of apoptotic pathways.


  • Open Access

    Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks

    by Georgy E. Leonov, Lydia R. Grinchevskaya, Oleg V. Makhnach, Marina V. Samburova, Dmitry V. Goldshtein, Diana I. Salikhova

    Regenerative medicine is a rapidly evolving field of contemporary biomedical research that offers new therapeutic strategies for conditions previously considered untreatable. Cell therapy shows particular potential in this domain. However, rigorous biosafety measures are required in its development and clinical application. This review proposes a practice-oriented biosafety framework for cell therapy, translating key risks into operational principles: toxicity, oncogenicity/tumorigenicity/teratogenicity, immunogenicity, biodistribution; and cell product quality. For each principle, preclinical approaches and regulatory expectations are summarized. Criteria for immunological safety are addressed, including activation of innate immunity (complement, T- and NK-cell responses) and the need for HLA typing. Biodistribution assessment involves the use of quantitative PCR and imaging techniques (PET, MRI) to monitor cell fate over time. The risks of oncogenicity, tumorigenicity, and teratogenicity can be analyzed using a combination of in vitro methods and in vivo models in immunocompromised animals. Product quality assessment includes sterility, identity, potency, viability, and genetic stability, with alignment of procedures to regulatory requirements and an emphasis on quality-by-design principles to ensure safe and reproducible clinical use. Integrating toxicity and safety pharmacology data supports a balanced risk–benefit assessment and clinical trial planning.